N
Google TrendPOSICIONES DE ATLÉTICO DE MADRID CONTRA MANCHESTER UNITED (5000+) — Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+luis díaz200+halle berry child custody hearing200+lamine yamal5000+thélyson orélien500+abdulrahman alfozan500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Chronic Plaque Psoriasis" (30 stories)

Top Headline Story

Icotrokinra sustains skin clearance in patients with plaque psoriasis
Lead StoryContemporary Pediatricstech
4d ago

Icotrokinra sustains skin clearance in patients with plaque psoriasis

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOb3NOT1NLallnTWl3SXVJREpiYWl4VU1RdFNUZXdWcHpxRVlvX3NiaE1FODVvN1o4bTFGSzJFSFktcGRsZUIzX3otdDB5VFpoSkJEdjZ6ZENzdzUwblQxQmpEcTd2Y1ZQQWJDSUpKVWhmNVRCYUFoMFlFdjk1THVRSVNwejhYTGo1QzRlMFJ5T3JnUE1aY2RkU2NDakdWUURfN2ZjYW9QeXoxTXJTdVF5UVZGcHpJOG4xOG1TV191Q2dodHlsUTlLMzhvbW5KeE1NR1E?oc=5" target="_blank">Icotrokinra sustains skin clearance in patients with plaque psoriasis</a>  <font color="#6f6f6f">Contemporary Pediatrics</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+22m ago

posiciones de atlético de madrid contra manchester united

Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League

Filter stories
2000+22m ago

devils vs red wings

Devils at Red Wings projected lineups

Filter stories
5000+22m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories
200+32m ago

luis díaz

Max Eberl knows Luis Díaz will start scoring again for Bayern Munich

Filter stories

Search Results for "Chronic Plaque Psoriasis"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
PR Newswireworld

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

<a href="https://news.google.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?oc=5" target="_blank">Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
At two years, at least 70% of patients on Johnson & Johnson’s psoriasis pill had clear or almost clear skin.
Stock Titangeneral

At two years, at least 70% of patients on Johnson & Johnson’s psoriasis pill had clear or almost clear skin.

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNYWhGSGZBX1B4UU15Njh4bURROUVmTTJaNl9ldjE3Z3lhYW1sQ0VrNDYxdzNZOExZRmRRMDAtRkJFLUdPcnY1V1h6X1RZd1BmNUgyU2FadHBMRWJmVUs0NjlpOVMteFNqVXRSel9uY29DeHI0dVJlNF9SN3ZBRS1sRkloRlo1T1lHcnYtcFdLSl9mdXdheklPLWJWTlA2U1BRX25qZ2ZYS2NxckdQVFZmVzhuLXVaNktKbDhnSw?oc=5" target="_blank">At two years, at least 70% of patients on Johnson & Johnson’s psoriasis pill had clear or almost clear skin.</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
Rapid resolution of guttate psoriasis with upadacitinib: a case report
Frontiersgeneral

Rapid resolution of guttate psoriasis with upadacitinib: a case report

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQUGFpeEp4QjVZc29BVnAya21nY3dNbUphRUc4bjRrUEhYMllteHM1Um1IbWY4VGdRWDVJNmRTNENOWmZyX0xIbG1VaWNWMGwzREVkbGZVamZGbmhJLWNPVXNIcUZva1cxdmt5UXVRWUNjZEJwRUtCR0J2WlJ2QXcwQjJQMk9vRHNYN3pDVzV3?oc=5" target="_blank">Rapid resolution of guttate psoriasis with upadacitinib: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Chronic Plaque Psoriasis With Persistent Facial Involvement Successfully Treated With Risankizumab: A Case Report
Cureusgeneral

Chronic Plaque Psoriasis With Persistent Facial Involvement Successfully Treated With Risankizumab: A Case Report

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQQ3NndjZPaU1JNlVFazR1Ul9rM0hjZzlJUV9BRnZsdHJwNUhCWnlYZDRrbkxQV2FlaXdOMHpCZENBVHNTRlNJckxoY2dFRVA1S09Nak1fZk5yYUZOLXA2UmVSbG1YYWhlQ1ROV3BVLXc0eWExSjlUZzJRVFp0WUd1eFNmX01EVHBfblp5aElCTFU3ekVNaV9BRVdzcWcteHpMemZlVXV2WDZHdkZ5LUQ2Ym9fTDExeW1DVURONjVKUUk1MUFZeEFLS1VWczk5NEowcDlZQWxhNThtWWFMZ2loOU95dHRxdw?oc=5" target="_blank">Chronic Plaque Psoriasis With Persistent Facial Involvement Successfully Treated With Risankizumab: A Case Report</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Management of chronic plaque psoriasis with... : Journal of Research in Ayurvedic Sciences
Ovidscience

Management of chronic plaque psoriasis with... : Journal of Research in Ayurvedic Sciences

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPUVc1b0RSdWo2WTZOeGtUeFJMUG1fN2NFdlQyTmRIUzJGMjgxbEJBalJ2b1ZCZFlJbTlkTnlhYk5pa2JPQl8ybXZyWkh3VkJYSUJWUG5neElPQ0hqV1hwZDhQRHZVaGYxSTRkU3F1ZGNoTGFVWEwzcFRPVDRKSGVqZ2hULVlIU09Wd0E4VV9CVlFnVWY1RTVvdlRJMkNESENpWFJIMTUyVWJ4OWx6YTZ3TG02Umtmdw?oc=5" target="_blank">Management of chronic plaque psoriasis with... : Journal of Research in Ayurvedic Sciences</a>  <font color="#6f6f6f">Ovid</font>

Read Full StoryMore like this
Journal of the European Academy of Dermatology and Venereology
Wiley Online Libraryworld

Journal of the European Academy of Dermatology and Venereology

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE9DT1JOYTRKakpQRllYRlplakRCWVNRUzh2VDNKTFdUaGtXQ3NQMHNLZDhrb2dzQzI2V21kUkdDSG5BdXNxS29JODRPLXUwOGpHUkhidkxIZDUyc044QnNqNUJNRzVSTWtjdXc?oc=5" target="_blank">Journal of the European Academy of Dermatology and Venereology</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Neuropsychiatric Manifestations of Acitretin-Induced Hyperhomocysteinemia in a Patient With Chronic Plaque Psoriasis
Psychiatrist.comgeneral

Neuropsychiatric Manifestations of Acitretin-Induced Hyperhomocysteinemia in a Patient With Chronic Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPWUVPTTRFWmE5V2pRQkdEV05aR2NpS1V1U2dWVkVUZmIzNjhUUTBHRjhGaFN1Y3BvMWlWMmRVelVZakFUaHJhMEFHMUdJaVpEeUpobjBtVE9ZRzhuQ193TzdoSDBCZ1oydjhfUUNvaFB5NEVBYWVkVjg3SFkwbkhEUlUzZVNFUWZwRVdBdzFtY2J1R2JieEE?oc=5" target="_blank">Neuropsychiatric Manifestations of Acitretin-Induced Hyperhomocysteinemia in a Patient With Chronic Plaque Psoriasis</a>  <font color="#6f6f6f">Psychiatrist.com</font>

Read Full StoryMore like this
FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis - MPR
Medical Professionals Referencegeneral

FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis - MPR

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5wSHhBZU9aMUU4VGlOMkNBSGtZOTNDbUdBOFRjTnNXb3hkMmdzTkwzZnRhMy1zdWdhZjMtckpUYXpsdEI3ajZoRmRpWUFWY2JIbXF4VlJIZm10YS1IdkZHX2FIYWtEQnhpTGhBaXlSN2w3MjRlcVNr?oc=5" target="_blank">FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis - MPR</a>  <font color="#6f6f6f">Medical Professionals Reference</font>

Read Full StoryMore like this
Achieving Long-Term Control in Plaque Psoriasis
Medscape Referencegeneral

Achieving Long-Term Control in Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQTFlRNUxwREs5X0RlRnZ3Y0hZZjVGZmRQYjQ2VDk5d2F1b21EYVMxSE1CN0Z1VUhmSHpWc0JYaV9TakpsM0Z4Qzg1TnljUFZhUU5acVQ5cU50VkhVT1hyeDZpUmhycTNydXFzT3pKSlBVTk5FblRXRzduazNJSzFNblV3cGxORVFZeGNhSTFIdHpTV3g3X2lYamFweWI2NzMtUHRENw?oc=5" target="_blank">Achieving Long-Term Control in Plaque Psoriasis</a>  <font color="#6f6f6f">Medscape Reference</font>

Read Full StoryMore like this
Zasocitinib for Psoriasis | Derm Immuno Today
DocWireNewsworld

Zasocitinib for Psoriasis | Derm Immuno Today

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNbjQ1ejg2WDQwbnRqS3k0NkI4RXl0WGhLN0E4anpLMk1VT3kzZ0ZQanFXYmZGV1QwVXFyU2xRaV9zUEVSeFhyLWQ4SzVMdFJjUFVENE9NV2dENVJpZnNYajRIZjRyTDBRakdxelZvSVRUWnFVcDhwMjY4NURnSExhNzk4WDNjV3A1VGM1SXdCMDU5dw?oc=5" target="_blank">Zasocitinib for Psoriasis | Derm Immuno Today</a>  <font color="#6f6f6f">DocWireNews</font>

Read Full StoryMore like this
Icotrokinra for Moderate-to-Severe Plaque Psoriasis: A Dermatologist's Guide for Primary Care
Patient Care Onlinegeneral

Icotrokinra for Moderate-to-Severe Plaque Psoriasis: A Dermatologist's Guide for Primary Care

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPUEFDWkhlTzJHS3p6MWxnTXkwU3hnM2gtR2tTYWt2a0lYMERmWkp2aUZOU2ZhNnktemZEV1plbkE3OXo0Q0V2a2plMWczc0xFaUQ5Z0UxNXU3czBCRVRUblhqc2IxUF9kWTBkcjYta0x2WElhaXpLZm1zM25xWGM0WWJFUWcwWE9TZDV5aG9mREJ5NzFxNURPb3dhcU1PSU1UVU9WSUhkLVE2TlFibE03WnJSNDY0b1FDVzFpLXQtUFVITWpEc3lFaFJ3aw?oc=5" target="_blank">Icotrokinra for Moderate-to-Severe Plaque Psoriasis: A Dermatologist's Guide for Primary Care</a>  <font color="#6f6f6f">Patient Care Online</font>

Read Full StoryMore like this
First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis
European Medicines Agency (EMA)general

First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPXzhYMVg2RW9fa0Y3am9EbzByNk5wQWM0cDFOcW56aXNVLWdLUTNJQWNjT2NzWDZnUVE0bE5WMWkta0RyWnhfZkZkTG5NejBQN0F6eUNNcEtHNFQ5cVVOdldHcllBazJ4T3psTEJScVdCSFlBdXFWd3RRcWlIbmlzc2Ryd2tvaGNUOG9fZUtNenRLaVBIekNqaDJ1WTNZNnBhMEd3aXVrR09xLWsxN2w0UmdOQXVKUHM?oc=5" target="_blank">First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis</a>  <font color="#6f6f6f">European Medicines Agency (EMA)</font>

Read Full StoryMore like this
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab
Naturegeneral

A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9tZ2VxTjN3SWNjZXJQWVpWSVR5ODZNUVkxN1BPcDFNLXkyM29naGJQbGtUdm9UejUyVmRSSmI4V1E2SUpqSHFxZTBUWGcybzE3NFRYOURVM29SUEhtYUt3?oc=5" target="_blank">A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Chronic Plaque Psoriasis as a Predictor of Spinal Osteoproliferation on Magnetic Resonance Imaging (MRI)
Cureusgeneral

Chronic Plaque Psoriasis as a Predictor of Spinal Osteoproliferation on Magnetic Resonance Imaging (MRI)

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZ0NWQXB1cFZsdE9GU1M2bWViTGZQWnRkMnp6S0REMVZkSEZTeGZPV3NWei1xRWZoRXRCMmg0NG01dC1fTlkzVU95Um5EWWJ3XzhNQm5BNF83d2ZiLTFyNVpKTUlRcVF5WHk5TzJEajlWN29fX0ZfcnZadm1DaGdVaXEwSWZDbjZ5Xy1xLVJlaDJ3T2NySXRKdGxraEZQSlozQ2NORWNUZVc1d1pMQm43c0U2cHdWVk1KSU1fblRjcDVWRmdzcGQ0WlJadVBqNllIS3V0U0Z1V0E?oc=5" target="_blank">Chronic Plaque Psoriasis as a Predictor of Spinal Osteoproliferation on Magnetic Resonance Imaging (MRI)</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Evolution of the psoriasis therapy landscape
Naturegeneral

Evolution of the psoriasis therapy landscape

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBkQWpHdkxOa255V1h0YmlHSjgzVlJxODR0d2RHQUE5WmpWUkdtQUlmSUJkUk1tNktfVmNnUWFPbWZpenFLWjVxa3ZlMjVCLXpaZ3I1TDRWTE9FZmtBdkVF?oc=5" target="_blank">Evolution of the psoriasis therapy landscape</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Comparative Efficacy of Interleukin Inhibitors and JAK Inhibitors in Moderate to Severe Plaque Psoriasis
Cureusgeneral

Comparative Efficacy of Interleukin Inhibitors and JAK Inhibitors in Moderate to Severe Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQVUdmbkEwNm1vamlWTG5aa2JyRmVUTEFQWjJpYTcyNzlTeGJVLXpwSS1TM3RPVWNfc0pCTllOWHZCLTYxNk1vWkQyUjJmRXdUT0VXTmgwSml0YXdvZ0lpTHhtQjdncTREbTdBVVZtUkVmYVJYU1VrczFXb2N0cUlaeW1QUW4tb1JCVGI4VnVHV09fTWZ4RmdkNkItZGM0bWRxYVVLZFo5dlZVWXVMVEN4STB0cU55bWg3dzNpbnMteElwN3pacnRRbG9GaFpvRDdUdnpFalh2QlZDam8?oc=5" target="_blank">Comparative Efficacy of Interleukin Inhibitors and JAK Inhibitors in Moderate to Severe Plaque Psoriasis</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
A Comparative Study of Oral Tofacitinib and Oral Methotrexate in the Treatment of Patients With Moderate to Severe Chronic Plaque Psoriasis
Cureusgeneral

A Comparative Study of Oral Tofacitinib and Oral Methotrexate in the Treatment of Patients With Moderate to Severe Chronic Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxOMGF3T3BBVXpGcWY3M3RPQ0dsWnFCVVFXYWlmRzhZOXFuT09JVWR5TmxLbFNtemU4Y1pYUDlRSjlLNW5qRmRYM1hkME8zVHFCVXRTVE1SQktVbUZrdEJsU3FrUUFTMTdxRXpEeDVKOFJDZmR0bkM2aFRIbVQxM0MzOWwzaDBHWmJYZXZDTVhFTVVqWjB4QnBUeDR2QWRJaDlBVnVWSlNzQ1ZfbzhXNjdsSVZqRGl3ZkVVektxUlVwOXdhT280NGc1cWZCcDM2cGhSNThhczdXTmVLYUZ4SkNmcDVCME9CRmNTVTBZYXRCbTAtV2MxblB6aEdiTjl5QkdnYW5ENVk1RVRJUQ?oc=5" target="_blank">A Comparative Study of Oral Tofacitinib and Oral Methotrexate in the Treatment of Patients With Moderate to Severe Chronic Plaque Psoriasis</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Cureusgeneral

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOZW9WdndZQmtSdl9sZ2gzRW9YRmZIQlhyY3N5YkxjbXNDVWtOaEEyOWZkdUUtdnNLVHJZNXpDRGRfSXdEc1plSUZFN09SS25LWGRINjBkcDJ3ME1NRmRwQXlJYVJlYk1CUkxPSlE4RWdqRWItSmFxTTB4MzNlYUR1dFZ2ZFdrMncwVjEybTY3VXh0LUZZU0NOdXpBalBrY1RacUNiLTVCdnJ3M1ZmMl8yVTFUN05yR2pjTjh3TzBhOUpoa0w2U3BvYm1GNmVIWWdxMTNSTWNCTnVhNGNUQmJr?oc=5" target="_blank">Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Severe Dupilumab-Associated Psoriasis Flare After Switching From Ustekinumab for Biopsy-Proven Eczematous Dermatitis: A Case Report
Cureusgeneral

Severe Dupilumab-Associated Psoriasis Flare After Switching From Ustekinumab for Biopsy-Proven Eczematous Dermatitis: A Case Report

<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxNd0JObl9obk5xNlBvSUFOOXcxcEJlU1pqeWRNMmcta25vMWJaaWpuUEtFZmthelR6Qkh3Q29KOUpBd1ExNzQ4ZnRjWklHMldxYkJuX0pObThqWk5WeGN4REVjY1lobHJ5ZU8ya1NjbXpOOWE2Nlk2VnJHU0tZM1d3ckZfS0hhaFprd3dUQWNfcm56TVBGLU9PTDUzNm5iSkFqZ2ZBQ0Y2ZXN2bzBfaW83OHN1NlpZTk4xTFIwcXhoSXdoWG0tdkZSU2JsVExtQ05Jd0dkX0xGYTRDaFVyUFplMWc4ZGJUSDBVcGpza2toQmxRMmVHbFh5czZsb19qUQ?oc=5" target="_blank">Severe Dupilumab-Associated Psoriasis Flare After Switching From Ustekinumab for Biopsy-Proven Eczematous Dermatitis: A Case Report</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Psoriasis Biosimilars Safe & Cost-Effective
Physician's Weeklygeneral

Psoriasis Biosimilars Safe & Cost-Effective

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQMk9CREhPN2ZZc2k5QW1qVHJHMUFrYjJUMDRtOTRYam5UMWpJLVJLaEN2MzZxMWNqc0xwdjRET2Z6MmFZRmpHYVYtN3dlb2ExT2huNXc1Q0J1YktzaHZXb0NYOVdQY09GVXdNMV94dHBZYm5Lem4zM2tLVXlEY19rTEJERVJGVTgtc0NEaU9valBuVGZnNjg3S3I0UkxQVzJxcnhnZFAtQkFTRzhV?oc=5" target="_blank">Psoriasis Biosimilars Safe & Cost-Effective</a>  <font color="#6f6f6f">Physician's Weekly</font>

Read Full StoryMore like this
FDA Approves Icotrokinra as First Targeted Oral Peptide for Moderate-to-Severe Plaque Psoriasis
Pharmacy Timesgeneral

FDA Approves Icotrokinra as First Targeted Oral Peptide for Moderate-to-Severe Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNM0pNSDJDTy1zWm0zNEl4N3dMQXlJU1NCMzlLZVNkNExnVG83aU9OWDFPbU5uM2JRTUk4VzZkN19aa2NTNl9TU2dxVnFGcmpFa0ZtYzd4dXpwdThVWjJhUjF6dUh3RHRqbm90SzVxeGNTdmtkNnJsSFZfVjd1YmY0ZFBOMkJmZndIU3hSeF9Sb2dtb1BJUGtDejQyWXBrUVRjR1lBYk54Z3NHX25McVdjWEhyY0JFMWVHVFU4Ty1haFRCdVhObGc2OF9R?oc=5" target="_blank">FDA Approves Icotrokinra as First Targeted Oral Peptide for Moderate-to-Severe Plaque Psoriasis</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Risankizumab Versus Icotrokinra: New Data on Adults with Moderate-to-Severe Psoriasis
HCPLivegeneral

Risankizumab Versus Icotrokinra: New Data on Adults with Moderate-to-Severe Psoriasis

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPNHNxYktHMHRsT1NOY013U0M5dTM2TVpEYVF3QlBuZVplUTdLaVJJdHplTVByM3NlWV96a1ljZWNKYTRSMTBiY0drMlhNNVFJUDNDS1JOZG9jUS00am1fYTNydmRMaUFMZGtTSHR5T3lrU3pxNTBRbnZEeU1VWjFqQ1NvSXRGNXBaZG05ek9UYmZ6ZmxURl93d2RoLU5QeUNadFk0Uw?oc=5" target="_blank">Risankizumab Versus Icotrokinra: New Data on Adults with Moderate-to-Severe Psoriasis</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
PR Newswiregeneral

UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMitwJBVV95cUxPdF9fY1ZiajYycExFWTZEVWxDaU1aME03SkY5aW55VjVyZzI2SmdFLURVWlU2OUV6Z1pFNmFUaEZjVWdDZzhoQVlkZ2JNRmNUdU52VFNnNXVjdV84dTFQQ3dMaUZWcWxOODhIN0NyRlNtM0pGYjZqUndJSTUyd0txTzM4WGhIbnMtQndLZXRLd3lmYjVwb1ZTTFRMT1BwMWdndjlCdUZIZWtIRDZ6RHZFbXRkTFczeEoyN1V0ckdZWkdvRnBuLXNraGFiNHRVbW0wcC1pbHJmSFNsWlhGMzJkY2FJNWRCTVJPSkN3TkR3OXo2SDViZlpWTmtTZ1ZZb0lNQ3c0ZXlqX1NFYjEzZzdyVHl0M0s3RGFCb1VmbEJPbXZnVjZCVDFjZGU2NnZxSFZOUkFLUVo0dw?oc=5" target="_blank">UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Tildrakizumab's Real-World Efficacy in Psoriasis
Physician's Weeklyworld

Tildrakizumab's Real-World Efficacy in Psoriasis

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxONDU2UUxxc3lfUzJDZGc3alJDc0xvWUlwelFwR3F0T1J6XzVHVkdmMXlyaURpVldRR1VpTGt2TjJmYmpidzlEeXNoeVBhbHZmaVVsSG5MMkpQSFgwQllkaTQ2YXdKMGFYOFp2VC1tak5pQ0lzVGRJNE1PT0ZwcG1IeU8xbUpZSExqUnIxdmdaT3lDQkpaQWk2al9R?oc=5" target="_blank">Tildrakizumab's Real-World Efficacy in Psoriasis</a>  <font color="#6f6f6f">Physician's Weekly</font>

Read Full StoryMore like this
Icotyde (icotrokinra) Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
Consultant360general

Icotyde (icotrokinra) Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQdjV4VFdEYmFMeHhPV281QmlNcFpNUldoZGpTOG4xcFRnMFFQSjRZcXQzNXZqNVF6SnlVQ25PTTRiSlBUbnRub1dtRE5YVUtfS2JidElmX0RFRE5Ba2M0Q3hvQ1hma09EWHhaeFlwWWtHZUxITllRRUxOeFpRY3pNVGQybEVMbFktMHNUWUplQVJ6a1VqMlJ4elF2a2I4UDd1NXowM0dtWnF0dGxDcHh1SWo2alVfQQ?oc=5" target="_blank">Icotyde (icotrokinra) Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis</a>  <font color="#6f6f6f">Consultant360</font>

Read Full StoryMore like this
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
Patient Care Onlinegeneral

FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNdHI5eXFucmNhbTV5X2Y1T1kwanRybE8xX2ZIeEEwTHIxQTg3endKZi13aFZiTXRzRkk1M0FXdjlIaE9KQldFNEVGYlptU1lmQkIyRWZtTjl3eHdKMnZHdVBmaHZQOW5hckdRT3RSMHo0clh1TjdkQklwdUZtLVVoNWdlb3pQbDMyUnVZRjRBTFFoNWEwSWRnVWd0UFpoaUxtcjhj?oc=5" target="_blank">FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis</a>  <font color="#6f6f6f">Patient Care Online</font>

Read Full StoryMore like this
Zasocitinib Phase 3 Data Demonstrate Rapid, Durable Skin Clearance in Plaque Psoriasis
Dermatology Timesgeneral

Zasocitinib Phase 3 Data Demonstrate Rapid, Durable Skin Clearance in Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxONGp5cHBfc2J3U3NKYU1qb2Q1N2JkcGFQeHBfNnRvaXBKTndiVTM5VmtYSkdFYWMzbWNyaE1MREhXTU5kYS1iTVJscTM4eW1CTmZXenJyUEVjZG9rUVJMbVJheEVOSTBwczJvaHFKWTB0QU1SSjFwRnpaZW5QUjBxblV5aWpaVVFldC1nLUotYk9MbHo3SlhoVkozQTQxa3AtVzVPbnJvbDBSYXhBT05sUkpYS0pfQkgzc1QzNzZTUzY?oc=5" target="_blank">Zasocitinib Phase 3 Data Demonstrate Rapid, Durable Skin Clearance in Plaque Psoriasis</a>  <font color="#6f6f6f">Dermatology Times</font>

Read Full StoryMore like this
Management of chronic plaque psoriasis with... : Journal of Research in Ayurvedic Sciences
Ovidscience

Management of chronic plaque psoriasis with... : Journal of Research in Ayurvedic Sciences

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQUkhMODRjdXFjNklVcFRadTZQUk5hWERvX0QwLUVrazZhRWEwUE94ckI1MUJjVWhCQjI2YUZKbnB4S1FpWUtoTEJhT1RLWC11MFlaYnZEbzZCVUREQVh4bUdieFVQREdqVDBLcTlTT0g3VlZUWW8wRHR6ZjF4amY2LWFkWUVEbFAzUXdnejVBVUpFNHFaYnpGWFhXX1VxU1RvREw2SjI1dUNvY3l1emNSSjBmOUNWQQ?oc=5" target="_blank">Management of chronic plaque psoriasis with... : Journal of Research in Ayurvedic Sciences</a>  <font color="#6f6f6f">Ovid</font>

Read Full StoryMore like this
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Yahoo Financeworld

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNSXR6dVZIbHBnY1BTTDJWVGNTenlsYVN0RWItV2ZPX29obkxScUdkRVczVEItbnEyekdDMElmWU4wWDAxNU1wTzY5VnRBNUNWOVR0aUgyelAtVWdRWWxfblBHLWppRllKb1JsTkF4ZHQtbUJ1VFc5ZFkwLTA1OURUbDdQWEVfZU5JY0tMMGsyUTFlZUJWRFE?oc=5" target="_blank">U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
"Chronic Plaque Psoriasis" — Live Google News Trends & Headlines